mofetil (MMF ) markedly reduces the rate of acute Background. In the first year after renal allograft trans-rejection episodes in the first 6-12 months after renal plantation, triple therapy immunosuppression with transplantation [1][2][3] [4] [5] [6] [7]. The excellent effects on the rate cyclosporin (CsA), prednisone (P), and mycophenolate of acute rejection episodes are in some contrast with mofetil (MMF ) is superior to a triple therapy treat-studies that show only a marginal effect of MMF on ment that includes azathioprine (AZA) instead of the incidence of chronic rejection. A 3-year follow-up MMF. Whether long-term treatment with CsA-P-of patients in European and in US multicentre studies MMF is better than treatment with CsA-P-AZA is a did not reveal a significant effect of MMF on graft matter of debate, as 3-year graft survival is similar in survival [8, 9] . Thus continued treatment with MMF MMF-and AZA-treated patients. The purpose of the may not be indicated for all patients. present study was to examine the short-term effect of Based on excellent preliminary results with early changing MMF to AZA in low-risk renal allograft conversion of MMF to azathioprine (AZA) we ranrecipients 6 months after transplantation.
Subjects and methods
patients in group A and group B was similar. Treatment failure rates (defined as clinically diagnosed acute rejection episodes) were 4.5% in group A and Study population 3.8% in group B. There were no patient deaths and no graft failures during the 6-months observation period. From June 1997 to July 1998, 94 adult renal transplants were performed at our centre. The standard prophylactic Graft function was excellent and similar in both were (i) clinically and/or biopsy-proven rejection episode Table 1 also lists the basic patient and donor characterwithin 6 months after randomization, necessitating at least istics, which did not reveal statistically significant steroid bolus therapy, (ii) slowly rising serum creatinine due differences between the two treatment groups.
to presumed mild rejection, necessitating a modification of Table 2 demonstrates that, except for MMF and MMF (group A) or AZA (group B) treatment, and (iii) AZA, the immunosuppressive regimens were comparside-effects due to AZA or MMF necessitating withdrawal able between the two treatment groups. In particular, of either immunosuppressive agent.
the Sandimmun NeoralA dosage as well as the CsA All patients were randomized at their routine 6 months levels at 6 and 12 months after transplantation did not ambulatory clinic visit. After randomization, patients were differ between the two groups, and prednisone dosage asked to either continue treatment with MMF (1 g twice daily) or to discontinue MMF and start with AZA (1 mg/kg was the same in both groups. The use of ATG was daily) the next day. Patients in both groups then had monthly less in group A patients (27 vs 46%, P=0.24).
follow-up visits for the next 6 months. Steroid withdrawal Table 3 shows that the incidence of acute rejection was attempted 9-12 months after transplantation, provided episodes was low in both groups in the 12-months the graft function remained stable. treatment interval after transplantation (9.1% in group A, 7.7% in group B), indicating, as anticipated, positive selection of low-risk patients with wellStatistical analysis functioning allografts within the first 6 months after Patient and laboratory data were recorded at 3-months transplantation. After the randomization, only one intervals from the date of transplantation up to 12 months treatment failure occurred in each group, representing after grafting. Baseline recipient and donor characteristics a success rate of 95.5% for group A (continued MMF ) and the laboratory data were analysed with descriptive and 96.2% for group B (switch to AZA). In group A statistics and were compared with the two-tailed t-test. one treatment failure was caused by a mild rejection Differences in categorical variables between the two treatment episode, which was successfully reverted with steroid groups were analysed with Fisher's exact test. The level of pulse therapy, and in group B one treatment failure significance was set at P<0.05.
was due to presumed mild rejection (slowly rising creatinine) responding favourably to a switch from AZA back to MMF. Steroid withdrawal was achieved
Results
in 27% of patients on continued MMF therapy (group A), and in 38% of patients on AZA (group B; Table 1 shows that the randomization could be P=0.54). achieved between 6 and 7 months after transplantation. Table 4 demonstrates that graft function was excellent in both groups. Creatinine levels were below well-functioning first renal allograft without severe rejection episodes. The general applicability to patients BMI, body mass index; CAD, cadaver donor; CAPD, continuous with a higher risk, for example regrafts or patients ambulatory peritoneal dialysis; HD, haemodialysis; LRD, living related donor.
with high panel-reactive antibodies, is certainly not warranted and may precipitate more serious rejection can be performed safely in low-risk renal allograft recipients. As MMF treatment is several times more expensive than treatment with AZA, this switch will *One treatment failure occurred in group A (a rejection episode, successfully reversed with steroid pulse treatment); **one treatment obviously result in substantial savings. Long-term failure occurred in group B (very mild rejection, successfully treated studies are required, however, to examine the safety by switching back from AZA to MMF ). ATG, antithymocyte and the economic implications of the MMF to AZA globulin; AZA, azathioprine; CsA, cyclosporin; FK506, tacrolimus; treatment switch. MMF, mycophenolate mofetil; P, prednisone.
